Combining chalcones with donepezil to inhibit both cholinesterases and aβ fibril assembly

Nishad Thamban Chandrika, Marina Y. Fosso, Oleg V. Tsodikov, Harry LeVine, Sylvie Garneau-Tsodikova

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


The fact that the number of people with Alzheimer's disease is increasing, combined with the limited availability of drugs for its treatment, emphasize the need for the development of novel effective therapeutics for treating this brain disorder. Herein, we focus on generating 12 chalcone-donepezil hybrids, with the goal of simultaneously targeting amyloid-β (Aβ) peptides as well as cholinesterases (i.e., acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)). We present the design, synthesis, and biochemical evaluation of these two series of novel 1,3-chalcone-donepezil (15a-15f) or 1,4-chalcone-donepezil (16a-16f) hybrids. We evaluate the relationship between their structures and their ability to inhibit AChE/BChE activity as well as their ability to bind Aβ peptides. We show that several of these novel chalcone-donepezil hybrids can successfully inhibit AChE/BChE as well as the assembly of N-biotinylated Aβ(1-42) oligomers. We also demonstrate that the Aβ binding site of these hybrids differs from that of Pittsburgh Compound B (PIB).

Original languageEnglish
Article number77
Issue number1
StatePublished - 2020

Bibliographical note

Publisher Copyright:
© 2019 by the authors.


  • Acetylcholinesterase
  • Alzheimer's disease
  • Aβ assembly
  • Aβ dissociation
  • Butyrylcholinesterase
  • H-PIB binding

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry


Dive into the research topics of 'Combining chalcones with donepezil to inhibit both cholinesterases and aβ fibril assembly'. Together they form a unique fingerprint.

Cite this